Navigation Links
RPCI-Led Study: FAK Inhibitor Proves Effective Against Brain Tumors in Preclinical Studies
Date:12/29/2012

Buffalo, NY (PRWEB) December 28, 2012

Researchers from Roswell Park Cancer Institute (RPCI) have published findings from a preclinical study assessing the effectiveness of a small-molecule inhibitor, CFAK-Y15, in treating some brain cancers. The paper, published in Molecular Cancer Therapeutics, demonstrates for the first time that inhibiting the protein focal adhesion kinase (FAK) with CFAK-Y15 is an effective approach to controlling growth of glioblastoma tumors, especially in combination with the standard chemotherapy agent temozolomide (Temodar).

FAK is overexpressed, or produced in excessive amounts, in tumor cells, and has been shown to play a key role in survival of cancer cells. In this study, a team led by Vita M. Golubovskaya, PhD, an Associate Professor of Oncology in the Department of Surgical Oncology, found that animal models treated with CFAK-Y15 demonstrated significantly prolonged survival compared to the control group. CFAK-Y15 provides FAK kinase-specific inhibition by upstream targeting of autophosphorylation sites on the FAK protein. It belongs to a class of ‘two for one’ compounds that also inhibit the oncoprotein Src by inhibiting its autophosphorylation.

“We found that CFAK-Y15 significantly decreased the viability of the glioblastoma cells, and in many cases appeared to cause tumor shrinkage — especially when CFAK-Y15 was given in combination with temozolomide,” noted Dr. Golubovskaya, the paper’s first author. “These compounds target FAK signaling, which is critical for cancer cell and cancer stem cell survival, especially in invasive and metastatic cancers.”

“We’re eager to see this research move to the clinical phase because of the great need for
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Nature Materials study: Boosting heat transfer with nanoglue
2. New Study: Health Professionals Support Biotechnologys Use In Food Products And Sustainable Farming
3. Nature Materials study: Graphene invisible to water
4. Breaking Study: ICU Medicals Tego® Needlefree Connector Proves More Cost Effective Than Traditional Central Venous Catheter Locks
5. Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
6. Array BioPharma To Present Clinical Data At The 2012 ASH Meeting On ARRY-520, A KSP Inhibitor, And ARRY-614, A Dual p38/Tie2 Inhibitor
7. Kinase Inhibitors: Global Markets -- Focus on the U.S.
8. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
9. Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications
10. Lixte Biotechnology Receives US Patent for Its Proprietary Histone Deacetylase Inhibitor
11. Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... , Apr. 1, 2015 Goldman Small ... the small cap and microcap sectors, announced today that ... Inc. (OTCQB – PMCB), a publicly traded clinical stage ... cancer and diabetes. To view the sponsored research article, ... in its entirety, please visit www.GoldmanResearch.com .  ...
(Date:4/1/2015)... , April 1, 2015  Among 1,050 U.S. consumers, ... oral cancer (68 percent) and only 36 percent reported ... check-up, according to findings from a survey ... leading innovator and developer of solutions that aid in ... The online survey polled 1,050 U.S. consumers on their ...
(Date:4/1/2015)... ROCKVILLE, Md. , April 1, 2015 /PRNewswire/ ... developer of pathogen-specific therapies for serious infections and ... today announced that clinical data supporting the development ... degrade certain beta-lactam intravenous (IV) antibiotics within the ... of the gut microbiome for the prevention of ...
(Date:4/1/2015)... 2015 Earlier this year, A.J. ... sciences industry association that represents research-based life science organizations ... Jonathan Parker, AJO’s Vice President of Business Development & ... an event that attracted over 750 attendees. , ... 73 year old cancer survivor shared his moving story ...
Breaking Biology Technology:Flurry of Biotech Mergers and Acquisitions Bodes Well for PharmaCyte Biotech 2Flurry of Biotech Mergers and Acquisitions Bodes Well for PharmaCyte Biotech 3Flurry of Biotech Mergers and Acquisitions Bodes Well for PharmaCyte Biotech 4National Oral Cancer Awareness Survey Reveals Greater Need for Education and Screening Tools for Oral Cancer Among U.S. Adults 2National Oral Cancer Awareness Survey Reveals Greater Need for Education and Screening Tools for Oral Cancer Among U.S. Adults 3National Oral Cancer Awareness Survey Reveals Greater Need for Education and Screening Tools for Oral Cancer Among U.S. Adults 4Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015 2Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015 3Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015 4HR Consulting Firm, A.J. O'Connor Associates Joins BioNJ – The Vibrant 400 Member Strong Life Sciences Industry Association - and Attends its Annual Dinner 2
... Memory,Pharmaceuticals Corp. (Nasdaq: MEMY ) today ... the Company,s request for an,extension until December 3, ... market capitalization requirement of $35 million or the ... order to remain,listed. There can be no assurance ...
... Aortic ... Aneurysms, ... of Vascular Surgery was the first to implant, in,Phoenix, the Powerlink ... aortic aneurysms (AAA). The procedure was,performed at Arizona Heart Hospital by ...
... BOSTON, Oct. 31 PAREXEL International,Corporation (Nasdaq: ... at the,Oppenheimer 19th Annual Healthcare Conference in New ... Financial Officer will be making,a formal presentation on ... 3,2008., The presentation will be available under ...
Cached Biology Technology:Memory Pharmaceuticals Granted Extension to Comply with NASDAQ Listing Requirements 2Arizona Heart Institute First to Implant Powerlink XL in Phoenix, Arizona Since FDA Approval 2Arizona Heart Institute First to Implant Powerlink XL in Phoenix, Arizona Since FDA Approval 3PAREXEL International to Present at Oppenheimer 19th Annual Healthcare Conference 2
(Date:4/1/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market, announces the second shipment of a ... early access pre-order customers. Feedback from ... including Walmart, Target, AT&T, Dunkin, Donuts, Stop & Shop ... all outlets and very easy to use. Several users ...
(Date:4/1/2015)... 2015   Medisafe ™, the leading global medication ... iOS and Android smartphones and tablets, ... the platform to allow patients to track and correlate ... time, patients will be able to visualize in real-time ... biometrics, such as glucose levels and blood pressure. ...
(Date:3/31/2015)... -- Elephant Talk Communications Corp. (NYSE MKT: ETAK) ("Elephant Talk" ... Network Architecture (ET Software DNA® 2.0) platforms and cyber ... million for the year ended December 31, 2014 as ... ended December 31, 2013. At the ... multi-year transition away from its legacy landline business to ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... is turning yellow. Do you gun the engine and speed ... green, or do you slow down and wait your turn? ... new research from Tel Aviv University. Arnon Lotem, a behavioral ... reports in the prestigious journal Nature that people adopt risk-taking ...
... PASADENA, Calif.-- Individuals with synesthesia perceive the world in ... their senses are ,cross-activated, some synesthetes perceive numbers or ... as possessing personalities, even ,as they function normally in ... Technology have discovered a type of ,synesthesia in which ...
... of York have helped to reveal more about the way ... could help in the development of new treatments for serious ... studied the way a protein found on the surface of ... fibronectin. Their discovery is an important step in understanding how ...
Cached Biology News:Humans' response to risk can be unnecessarily dangerous, finds Tel Aviv University study 2Caltech neurobiologists discover individuals who 'hear' movement 2Caltech neurobiologists discover individuals who 'hear' movement 3
... cassette is designed to allow ampicillin selection ... gb2 driving the gene for ampicillin resistance ... Em7 promoter. It mediates higher transcription efficiency ... synthetic polyadenylation signal terminates the ampicillin expression. ...
... The PRO S-7 stirrers ... Spill-resistant housing channels fluids away ... panel features easy-to-use controls which ... 7"x7" ceramic tops feature ...
... loxP-cm-loxP cassette is designed to ... The prokaryotic promoter gb2 driving ... a slightly modified version of the ... efficiency than the generally used Tn5 ...
... This kit is designed for the ... large vector plasmids at any position (for ... included loxP-PGK-gb2-neo-loxP cassette is designed to allow ... eukaryotic cells. It combines a prokaryotic promoter ...
Biology Products: